GLP-1 receptor agonists may improve lung cancer outcomes
Lung cancer patients who take medications called GLP-1 receptor agonists—commonly prescribed for weight loss and diabetes management—fare better than those who don’t, according to research led by Sai Yendamuri, MD, MBA, FACS, Chair of Thoracic Surgery at Roswell Park Comprehensive Cancer Center, and Joseph Barbi, Ph.D., Assistant Professor, Department of Immunology. Results of the study, […]
Will LLY’s Oncology Portfolio Provide Key Diversification Benefits?
Eli Lilly’s LLY extraordinary revenue expansion remains anchored in its cardiometabolic franchise, where blockbuster GLP-1 drugs Mounjaro and Zepbound powered $20.6 billion in sales during the first half of 2025, up 58% over the prior-year period. Oncology, while not the primary growth driver, contributed $4.4 billion in revenues, representing a 10% year-over-year increase and constituted […]
Drug pricing watchdog finds weight-loss drugs are becoming more cost-effective
Popular GLP-1 weight-loss injections like Ozempic or WeGovy are now delivering greater value, according to a new report
Regeneron’s promising antibody for cat, birch allergies; Ascletis targets quarterly GLP-1 shot
Plus, news about Anavex, Alnylam, Rapport Therapeutics, Dianthus Therapeutics, Ultragenyx, Atom Therapeutics, Alchemab, BioMarin, Amgen, Kyowa Kirin and Bristol Myers Squibb: 🤧 Regeneron’s allergy drugs clear Phase 3 trials: The company’s allergen-blocking antibody candidates …
STAT+: Lilly looks into gene therapies for obesity
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. It’s STAT’s tenth anniversary! We’re so grateful to all of you for reading and supporting our work. Onto the news today. Continue to STAT+ to read the full story…
Pricing Group Says Weight-Loss Drugs Becoming More Cost-Effective
By Deena Beasley(Reuters) -An influential drug pricing watchdog on Tuesday said popular GLP-1 weight-loss injections have become more…
GLP-1 weight-loss drugs pose hidden risks for young women, warn experts
Women taking popular weight-loss medications during their reproductive years may be unaware of associated risks to pregnancy and unborn babies, warn Flinders University researchers.
Healthcare, Vol. 13, Pages 2259: Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022–2025)
Healthcare, Vol. 13, Pages 2259: Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022–2025) Healthcare doi: 10.3390/healthcare13182259 Authors: Hadi A. Almansour Hilal A. Thaibah Moaddey Alfarhan Saeed A. Al-Qahtani Amani A. Khardali Thamir M. Alshammari Background: Tirzepatide (Mounjaro or Zepbound), a dual GLP-1/GIP receptor agonist, is approved for type 2 diabetes and […]
Are Greggs shares cheap enough to consider buying?
Greggs‘ (LSE:GRG) shares have lost around half of their value over the past 12 months. And I think thatâs probably fair. I thought the stock was trading at unbelievably high multiples for a company that has already conquered most of the UK geographically, and makes a tasty but not overly innovative products. The valuation we […]
FDA Announces ‘Green List’ of Foreign GLP-1 Ingredient Manufacturers
The Food and Drug Administration recently announced new measures to prevent the import of dangerous foreign counterfeits of GLP-1 drug ingredients, which are being used to make unapproved compound drugs targeting individuals seeking weight loss medication. On Sept. 5, the FDA announced the creation of a “green list” import alert for GLP-1 active pharmaceutical ingredients […]